It has been a few years since investors began to take note of the changing landscape of the health industry. #HealthTech is blurring the lines between medical technologies, digital devices and diagnostics.
The COVID-19 pandemic has accelerated the digital transformation in healthcare faster than ever imagined.
We are geared towards a complete shift in the way healthcare data is collected, monitored and shared to support the rapidly evolving needs in healthcare delivery. #Healthtech industry shows signs of resilience in the current market environment given revenue models, lower cyclicality and increase demand for affordable healthcare services. Innovations in patient engagement coupled with remote healthcare monitoring technology and #AI will reshape the way healthcare is accessed. We are at the cusp of that point where digital health will no longer be viewed in isolation. #HealthTech is the new face of the industry and is here to stay. Forever!
We tried to cover some healthcare IT industry trends in the M&A space.
- The global healthcare technology market is projected to reach USD 390.7 billion by 2024
- Strategic M&A surpassed USD 8 billion in the first half of 2020, which demonstrates the growth and increase in interest for healthcare technology in the current climate.
- Total deal value in venture capital and corporate M&A are on pace to double 2019 values, with notable transactions currently in progress including Teladoc’s acquisition of Livongo for USD 18.5 billion
Access the full “HealthTech M&A Insight September 2020” below
This section of the website sets out a variety of materials relating to the investment banking and private equity to be used for educational and non-commercial purposes only; the author(s) of the blog do not intend the blog to be a source of legal advice. Please retain and seek the advice of a professional and use your own good judgement before choosing to act on any information included in the blog. If you choose to rely on the materials, you do so entirely at your own risk. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any division of Columbia Pacific Capital Partners Inc. (CPCP)
Share this Post